高级检索
当前位置: 首页 > 详情页

Recognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKG2d-ligands recognition.

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Oncology, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, China [2]Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China [3]Guangdong Provincial Key Laboratory of Cancer Immunotherapy and Guangzhou Key Laboratory of Tumor Immunology Research, Cancer Research Institute, Southern Medical University, Guangzhou, China [4]Department of Pathology, Guilin Medical College, Guilin, China [5]Department of Anatomy, Guangdong Provincial Key Laboratory of Construction and Detection in Tissue Engineering, School of Basic Medical Science, Southern Medical University, Guangzhou, China [6]Children’s Hospital Boston, Harvard Medical School, Boston, MA, USA [7]Institute of Comparative Medicine & Laboratory Animal Center, Southern Medical University, Guangzhou, China
出处:
ISSN:

关键词: Cancer stem cells cytokineinduced killer cells hepatocellular carcinoma in vivo bioluminescence imaging NKG2D-ligands recognition promoterreporter gene strategy time-lapse recording

摘要:
There is an urgent need for more potent and safer approaches to eradicate cancer stem cells (CSCs) for curing cancer. In this study, we investigate cancer-killing activity (CKA) of cytokine-induced killer (CIK) cells against CSCs of hepatocellular carcinoma (HCC). To visualize CSCs in vitro by fluorescence imaging, and image and quantify CSCs in tumor xenograft-bearing mice by bioluminescence imaging, HCC cells were engineered with CSC detector vector encoding GFP and luciferase controlled by Nanog promoter. We found that CIK cells have a strong CKA in vitro against putative CSCs of HCC, as shown by tumorsphere formation and time-lapse imaging. Additionally, time-lapse recording firstly revealed that putative CSCs were attacked simultaneously by many CIK cells and finally eradicated by CIK cells, indicating the necessity of achieving sufficient effector-to-target ratios. We firstly illustrated that anti-NKG2D antibody blocking partially but significantly inhibited CKA of CIK cells against putative CSCs. More importantly, intravenous infusion of CIK cells remarkably delayed tumor growth in mice with a significant decrease in putative CSC number monitored by bioluminescence imaging. Taken together, these findings demonstrate CKA of CIK cells against putative CSCs of HCC, at least in part, by NKG2D-ligands recognition.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 2 区 医学
小类 | 2 区 免疫学 2 区 肿瘤学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 免疫学 2 区 肿瘤学
第一作者:
第一作者机构: [1]Department of Oncology, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, China [2]Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China
共同第一作者:
通讯作者:
通讯机构: [3]Guangdong Provincial Key Laboratory of Cancer Immunotherapy and Guangzhou Key Laboratory of Tumor Immunology Research, Cancer Research Institute, Southern Medical University, Guangzhou, China [7]Institute of Comparative Medicine & Laboratory Animal Center, Southern Medical University, Guangzhou, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2021 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号